Target Name: CD3E
NCBI ID: G916
Review Report on CD3E Target / Biomarker Content of Review Report on CD3E Target / Biomarker
CD3E
Other Name(s): CD3-epsilon | CD3epsilon | CD3 epsilon subunit of T-cell receptor complex | CD3e | CD3e antigen, epsilon polypeptide (TiT3 complex) | CD3e molecule, epsilon (CD3-TCR complex) | T3E | TCRE | CD3E_HUMAN | T-cell surface glycoprotein CD3 epsilon chain | T-cell surface antigen T3/Leu-4 epsilon chain | CD3E antigen, epsilon polypeptide | IMD18 | T-cell antigen receptor complex, epsilon subunit of T3

CD3E as a Potential Drug Target: Unlocking the Potential of CD3-Epsilon in Cancer Treatment

Introduction

CD3-epsilon (CD3-E) is a protein that is expressed in various tissues of the body, including the immune system, and is involved in the regulation of T cell responses. It has been identified as a potential drug target in cancer treatment due to its unique structure and its involvement in cellular signaling pathways. In this article, we will explore theCD3-epsilon as a drug target and its potential in cancer treatment.

CD3-Epsilon: Structure and Function

CD3-epsilon is a 22kDa protein that is composed of two major subunits, a 12kDa alpha subunit and a 10kDa beta subunit. The alpha subunit consists of a variable region that includes a single constant (C1) domain, a single variable region (Reg- 伪), and a single C-terminal hypervariable region (Reg-尾). The beta subunit is composed of a single N-terminal alpha helix, a single central 尾 strand, and a single C-terminal hypervariable region (Reg-纬).

CD3-epsilon is involved in the regulation of T cell responses, including helper T cell responses, memory T cell responses, and natural killer cell responses. It plays a crucial role in the development of CD4+ T cells and in the regulation of CD8+ T cells responses. CD3-epsilon has been shown to be involved in the regulation of several cellular signaling pathways, including the T cell receptor (TCR) signaling pathway, the inhibition of apoptosis (IAP) signaling pathway, and the regulation of inflammation (NF-kappa-B ) signaling pathway.

CD3-Eepsilon as a Drug Target

The potential of CD3-epsilon as a drug target arises from its unique structure and its involvement in cellular signaling pathways. One of the key advantages of CD3-epsilon is its expression in various tissues of the body, including the immune system, which makes it a potential drug target in cancer treatment. CD3-epsilon has been shown to be overexpressed in various types of cancer, including breast, lung, and ovarian cancer.

In addition, CD3-epsilon has been shown to play a role in the development of resistance to cancer chemotherapy. Studies have shown that patients with breast cancer who have high levels of CD3-epsilon have a higher risk of developing resistance to chemotherapy. This is because high levels of CD3-epsilon have been shown to inhibit the production of T cells that are responsible for detecting and destroying cancer cells.

CD3-Eepsilon has also been shown to be involved in the regulation of cellular signaling pathways that are involved in cancer progression. For example, studies have shown that CD3-epsilon is involved in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation and cancer progression.

Potential Therapeutic Strategies

CD3-epsilon has been shown to be involved in the regulation of multiple cellular signaling pathways, making it a potential target for cancer treatment. One of the key strategies for treating cancer is the inhibition of CD3-epsilon, which can be achieved through various methods , including small molecule inhibitors, monoclonal antibodies, and adoptive T cell therapy.

One of the key advantages of small molecule inhibitors is their ability to selectively target a specific protein, such as CD3-epsilon, without affecting other proteins. This allows for a more targeted and effective treatment of cancer. For example, inhibitors of the enzyme cyclin D1 have been shown to be effective in inhibiting the activity of CD3-epsilon and have been shown to be effective in treating various types of cancer.

Monoclonal antibodies, on the other hand, are laboratory-produced versions of antibodies that are specific for a particular protein. They have the advantage of being highly targeted and can be used to treat cancer in a more targeted manner than small molecule inhibitors. For example , monoclonal antibodies against CD3-epsilon have been shown to be effective in treating various types of cancer.

Adoptive T cell therapy is a type of cancer treatment that involves the use of

Protein Name: CD3 Epsilon Subunit Of T-cell Receptor Complex

Functions: Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:2470098). In addition of this role of signal transduction in T-cell activation, CD3E plays an essential role in correct T-cell development. Initiates the TCR-CD3 complex assembly by forming the two heterodimers CD3D/CD3E and CD3G/CD3E. Participates also in internalization and cell surface down-regulation of TCR-CD3 complexes via endocytosis sequences present in CD3E cytosolic region (PubMed:10384095, PubMed:26507128)

The "CD3E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD3E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2